Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease

This is a preview of subscription content, log in to check access.


  1. 1.

    Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Q J Nucl Med Mol Imaging. 2017;61(2):168–80.

    PubMed  Google Scholar 

  2. 2.

    Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;0302-2838(19):30520–2.

    Google Scholar 

  3. 3.

    Thang SP, Violet J, Sandhu S, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2018;18:30205–0.

    Google Scholar 

  4. 4.

    Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.

    CAS  Article  Google Scholar 

  5. 5.

    Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Samer Ezziddin.

Ethics declarations

Conflict of interest

Authors KC, GFL and HU have a patent application for radiolabeled FAP-ligands. The other authors declare that they have no conflict of interest.

Informed consent and ethical approval

The reported patient gave written informed consent to receive the novel diagnostics and permitted publication of his case and medical data. This is a case report from clinical practice; no trial registration or IRB approval is needed for this kind of publication.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Khreish, F., Rosar, F., Kratochwil, C. et al. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur J Nucl Med Mol Imaging 47, 2040–2041 (2020). https://doi.org/10.1007/s00259-019-04623-x

Download citation